Add-on Onvansertib Overcomes Resistance to Zytiga in mCRPC, Early Data Show

Add-on Onvansertib Overcomes Resistance to Zytiga in mCRPC, Early Data Show
Adding the investigational oral therapy onvansertib to a regimen of Zytiga (abiraterone acetate) and prednisone overcomes resistance to Zytiga in men with metastatic castration-resistant prostate cancer (mCRPC), according to early results of a Phase 2 clinical trial. The study (NCT03414034) is testing whether a once-daily dose of Trovagene’s onvansertib is beneficial in adults with mCRPC who experienced cancer progression on Janssen’s Zytiga and prednisone. Patient enrollment is ongoing, for a planned total of 64 participants. (More information about contacts and the three U.S. locations is available here.) Patients with mCRPC typically develop resistance to standard-of-care medications such as Zytiga — an androgen-receptor signaling (ARS) inhibitor — within nine to 15 months of beginning treatment. In some cases, resistance develops when cells produce a variant of the androgen receptor, called AR-V7, that lacks the domain targeted by current androgen receptor inhibitors. In other cases, cancer cells overproduce the androgen receptor. In the ongoing Phase 2 trial, patients are receiving a blood test to determine if they have the AR-V7 variant. So far, the four
Subscribe or to access all post and page content.

Tagged , , , , , , .

José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

Leave a Comment

Your email address will not be published. Required fields are marked *